EDCTP Alumni Network

Fostering excellence and collaboration in the next generation of researchers

All Profiles
Call Senior Fellowship (SF)
Programme EDCTP2
Start Date 2017-04-01
End Date 2022-03-31
Project Code TMA2015SF1001
Status Active


Harnessing parasite diversity and naturally acquired protective immunity against Plasmodium falciparum malaria for the development of highly effective vaccines (SMART)


To support the development and maintenance of highly effective vaccines against Plasmodium falciparum malaria in the long term by: 1. Monitoring population-level antigen specific parasite diversity of a comprehensive panel of vaccine candidates 2. Investing in the human capacity for basic science research in sub-Saharan Africa

Host Organisation

Institution Country
Kenya Medical Research Institute (KEMRI) Kenya

Study Design

The project takes advantage of retrospectively collected samples that are available from multi-centre cohort studies (MCS). The MCS all employed a prospective longitudinal cohort study design, in which children were sampled at the start of the study and subsequently monitored for clinical episodes of malaria (end-point) through home or clinic visits over the subsequent 6 months to 1 year post-sampling. Parasites are genotyped from samples collected at the start of the study, and at all subsequent points during the observation period. The MCS included in this project were purposively selected to represent the broad range of malaria transmission intensities present in Sub-Saharan Africa.

Phd Study

Title University Start Date End Date
Immune responses to polymorphic antigens and protection against severe malaria in Kenyan children The Open University 2004-05-01 2008-11-13

Students Supervised

Type Name Title University Start Date End Date
PhD Student Akua Botwe KEMRI-Wellcome Trust Research Programme 2016 2020
PhD Student Karamoko Niare KEMRI-Wellcome Trust Research Programme 2017 2020
PhD Student Rokhaya Sane KEMRI-Wellcome Trust Research Programme 2018 2021


Vaccine candidate discovery for the next generation of malaria vaccines. Tuju J, Kamuyu G, Murungi LM, Osier FHA. Immunology. 2017 Oct;152(2):195-206.
The 2015-2016 Malaria Epidemic in Northern Uganda; What Are the Implications for Malaria Control Interventions?. Ogwang R, Akena G, Yeka A, Osier F, Idro R. Acta Trop. 2018 Dec;188:27-33.
KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization. Kamuyu G, Tuju J, Kimathi R, Mwai K, Mburu J, Kibinge N, Chong Kwan M, Hawkings S, Yaa R, Chepsat E, Njunge JM, Chege T, Guleid F, Rosenkranz M, Kariuki CK, Frank R, Kinyanjui SM, Murungi LM, Bejon P, Färnert A, Tetteh KKA, Beeson JG, Conway DJ, Marsh K, Rayner JC, Osier FHA. Front Immunol. 2018 Dec 11;9:2866.
Serological Profiling for Malaria Surveillance Using a Standard ELISA Protocol. Murungi LM, Kimathi RK, Tuju J, Kamuyu G, Osier FHA. Methods Mol Biol. 2019 Jul 2013:83-90.
Turning Discoveries into Treatments: Immunology in Africa. Osier F.H.A., Mwandumba H.C., Gray C.M. Trends in Immunology. Nov 2020

Send a Message